Amphastar Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol
Amphastar Pharmaceuticals has received FDA approval for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation Aerosol. This product treats and prevents bronchospasm in patients aged four and older and is bioequivalent to Teva's ProAir® HFA. Amphastar plans to launch the product in Q3 2024. The U.S. market for branded and generic albuterol sulfate inhalation aerosols was approximately $1.7 billion as of March 2024. Amphastar also has three ANDAs, three biosimilar products, and four generic products in development, targeting markets worth over $11.4 billion. The approval underscores Amphastar’s manufacturing capabilities and commitment to developing complex inhalation products.
- FDA approval for Albuterol Sulfate Inhalation Aerosol.
- Product is bioequivalent to Teva's ProAir® HFA.
- Expected product launch in Q3 2024.
- U.S. market sales for albuterol sulfate products were $1.7 billion (12 months ending March 31, 2024).
- Three ANDAs targeting $1.4 billion market, three biosimilars targeting $7 billion market, and four generic products targeting $3 billion market in development.
- Approval highlights technological and manufacturing capabilities.
- No specific financial figures or timelines for revenue generation from new product mentioned.
- Dependence on FDA approval for other pipeline products may pose risks.
- Potential market competition with established brands like Teva's ProAir® HFA.
FDA approval of Amphastar's Albuterol Sulfate Inhalation Aerosol can have significant
Competition with Teva's ProAir HFA might pressure Amphastar to price competitively, potentially affecting margins but offering volume growth. The announcement of a third-quarter launch ensures short-term revenue boost, important for near-term earnings.
Long-term, success in this market can bolster Amphastar’s reputation and finances, aiding future product developments. However, market share gain requires strategic pricing and strong marketing efforts.
The approval for Amphastar's Albuterol Sulfate Inhalation Aerosol is a testament to their bioequivalence with Teva's ProAir HFA, ensuring physicians and patients trust the new product.
Bioequivalence means the new inhaler delivers the same therapeutic effect as the established ProAir HFA, critical for patient adoption. This is especially important for a medication that treats bronchospasm, where consistent efficacy and safety are vital.
The short-term benefit is the expansion of treatment options, but long-term success hinges on maintaining rigorous quality standards and achieving high market penetration.
Amphastar's entry into the albuterol inhalation market, with IQVIA data indicating a
The FDA approval is not just a milestone for Amphastar’s product pipeline but also underscores their capability in developing complex generic drugs. This positions Amphastar to challenge existing market leaders and potentially drive down drug costs, benefiting both healthcare providers and patients.
However, Amphastar will need to navigate competitive pricing and ensure sufficient supply to meet market demand, which are critical for sustaining long-term market presence.
RANCHO CUCAMONGA, CA / ACCESSWIRE / May 22, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that the U.S. Food and Drug Administration ("FDA") has granted approval for the Company's Abbreviated New Drug Application ("ANDA") for Albuterol Sulfate Inhalation Aerosol, previously known as AMP-008. This product is for the treatment or prevention of bronchospasm in patients four years of age and older with reversible obstructive airway disease and the prevention of exercise-induced bronchospasm in patients four years of age and older. The FDA determined that Amphastar's albuterol is bioequivalent and therapeutically equivalent to Teva Respiratory LLC's ProAir® HFA (albuterol sulfate) Inhalation Aerosol.
Amphastar's CEO and President, Dr. Jack Zhang, commented: "Our first generic inhalation product's approval reflects both our technological and manufacturing ability. While patients can benefit from increased access to this combination drug product, we are proud to manufacture the finished product in the United States, as our commitment to quality remains our top priority. This approval sets a solid foundation for future growth in developing our other generic inhalation products, highlighting our expertise in developing complex products."
According to IQVIA, the U.S. sales for the branded and generic albuterol sulfate Inhalation Aerosol products were approximately
Amphastar plans to launch its Albuterol Sulfate Inhalation Aerosol in the third quarter of 2024.
Pipeline Information
The Company currently has three abbreviated new drug applications ("ANDAs") on file with the U.S. Food and Drug Administration (the "FDA") targeting products with a market size of over
Amphastar's Chinese subsidiary, Amphastar Nanjing Pharmaceuticals, Co., Ltd. ("ANP"), currently has multiple Drug Master Files ("DMFs"), on file with the FDA and is developing several additional DMFs.
Company Information
Amphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at www.amphastar.com.
Amphastar's logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar®, BAQSIMI®, Primatene MIST®, REXTOVYTM, Amphadase®, and Cortrosyn®, are the property of Amphastar.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the prospective benefits of the acquisition of BAQSIMI®, including its potential for continued revenue growth, the success of our integration of BAQSIMI®, and other future events. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 29, 2024 and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 filed with the SEC on May 10, 2024. In particular, there can be no guarantee that the acquisition of BAQSIMI® will be beneficial to our business, that any event, change or other circumstance could cause the results of the acquisition and integration of BAQSIMI® into our product portfolio to differ from Amphastar's expectation, that all or any of the contingent consideration will be payable on the terms described herein or at all, or that Amphastar can reliably predict the impact of BAQSIMI® on its financial results or financial guidance. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.
Contact Information:
Amphastar Pharmaceuticals, Inc.
Bill Peters
Chief Financial Officer
(909) 476-3416
SOURCE: Amphastar Pharmaceuticals, Inc.
View the original press release on accesswire.com
FAQ
What is the recent FDA approval received by Amphastar?
When does Amphastar plan to launch the Albuterol Sulfate Inhalation Aerosol?
How does Amphastar's Albuterol Sulfate Inhalation Aerosol compare to Teva's ProAir® HFA?
What is the market size for albuterol sulfate inhalation aerosol products in the U.S.?
What other products does Amphastar have in its pipeline?
